
  
    
      
        Background_NNP
        Recombinant_NNP viral_JJ vectors_NNS have_VBP become_VBN the_DT primary_JJ agents_NNS
        for_IN both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN gene_NN transfer_NN applications_NNS [_NN
        1_CD 2_CD 3_CD 4_CD ]_NN ._. Viruses_NNP are_VBP powerful_JJ gene_NN transfer_NN agents_NNS ,_,
        since_IN they_PRP have_VBP evolved_VBN specific_JJ ,_, efficient_JJ machinery_NN to_TO
        deliver_VB nucleic_JJ acids_NNS into_IN cells_NNS ._. To_TO our_PRP$ knowledge_NN ,_, viral_JJ
        vectors_NNS have_VBP almost_RB always_RB been_VBN used_VBN free_JJ in_IN solution_NN ._. For_IN 
        in_IN vitro_NN systems_NNS ,_, a_DT solution_NN
        containing_VBG free_JJ viral_JJ vectors_NNS is_VBZ applied_VBN to_TO target_VB cells_NNS ._.
        Similarly_RB ,_, free_JJ viral_JJ vectors_NNS in_IN solution_NN are_VBP administered_VBN
        locally_RB or_CC systemically_RB for_IN 
        in_IN vivo_NN gene_NN transfer_NN applications_NNS ._.
        Some_DT site-specificity_JJ of_IN the_DT delivery_NN of_IN viral_JJ vectors_NNS can_MD
        be_VB achieved_VBN by_IN applying_VBG a_DT solution_NN containing_VBG viral_JJ
        particles_NNS specifically_RB to_TO the_DT site_NN of_IN interest_NN for_IN both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN settings_NNS ._. However_RB ,_, such_JJ
        site-specificity_JJ is_VBZ seriously_RB limited_JJ since_IN viral_JJ vectors_NNS
        can_MD diffuse_NN freely_RB in_IN solution_NN after_IN application_NN ._.
        In_IN this_DT work_NN ,_, we_PRP have_VBP developed_VBN a_DT novel_NN strategy_NN for_IN
        virus-mediated_JJ 
        in_IN situ_NN transduction_NN of_IN target_NN cells_NNS
        on_IN solid_JJ surfaces_VBZ using_VBG adenoviral_NN vectors_NNS as_IN gene_NN transfer_NN
        agents_NNS ._. In_IN this_DT strategy_NN ,_, adenoviral_NN particles_NNS are_VBP
        immobilized_JJ ,_, tightly_RB and_CC stably_RB ,_, on_IN solid_JJ surfaces_VBZ ,_, while_IN
        maintaining_VBG the_DT natural_JJ properties_NNS of_IN the_DT viral_JJ vectors_NNS ._. We_PRP
        reasoned_VBD that_IN such_JJ immobilized_JJ viral_JJ vectors_NNS could_MD infect_NN
        cells_NNS only_RB at_IN the_DT contact_NN site_NN between_IN the_DT solid_JJ surface_NN
        and_CC cells_NNS ._. Thus_RB ,_, the_DT ultimate_JJ spatial_NN arrangements_NNS of_IN
        transduction_NN sites_NNS on_IN the_DT solid_JJ surface_NN could_MD be_VB controlled_VBN
        and_CC determined_VBN ,_, at_IN will_MD ,_, by_IN the_DT strategic_JJ placement_NN of_IN
        viral_JJ vectors_NNS on_IN the_DT solid_JJ surface_NN ._.
      
      
        Results_NNS
        
          Virus-mediated_NNP in_IN situtransduction_NN of_IN cells_NNS on_IN
          solid_JJ surfaces_VBZ
          We_PRP have_VBP developed_VBN a_DT novel_NN strategy_NN for_IN virus-mediated_JJ 
          in_IN situ_NN transduction_NN of_IN target_NN
          cells_NNS on_IN solid_JJ surfaces_VBZ using_VBG adenoviral_NN vectors_NNS as_IN gene_NN
          transfer_NN agents_NNS ._. In_IN this_DT strategy_NN ,_, adenoviral_NN particles_NNS
          are_VBP immobilized_JJ ,_, tightly_RB and_CC stably_RB ,_, on_IN solid_JJ surfaces_VBZ
          (_( virus-coated_JJ solid_JJ surfaces_VBZ )_) ,_, while_IN maintaining_VBG their_PRP$
          natural_JJ properties_NNS ,_, including_VBG infectivity_NN ._. We_PRP
          hypothesized_VBN that_IN such_JJ viral_JJ vectors_NNS ,_, immobilized_JJ on_IN a_DT
          solid_JJ surface_NN ,_, could_MD infect_NN cells_NNS only_RB at_IN the_DT contact_NN
          site_NN between_IN the_DT solid_JJ surface_NN and_CC cells_NNS ._. This_DT could_MD
          allow_VB the_DT spatial_NN control_NN and_CC arrangements_NNS of_IN
          transduction_NN sites_NNS on_IN a_DT solid_JJ surface_NN ,_, which_WDT can_MD be_VB
          determined_VBN by_IN the_DT strategic_JJ placement_NN of_IN viral_JJ particles_NNS
          on_IN the_DT solid_JJ surface_NN ._.
        
        
          Infectivity_NNP of_IN biotinylated_JJ adenoviral_NN vectors_NNS
          immobilized_JJ on_IN solid_JJ surfaces_VBZ
          The_DT feasibility_NN of_IN this_DT strategy_NN was_VBD tested_VBN by_IN using_VBG
          recombinant_JJ adenoviral_NN vectors_NNS carrying_VBG a_DT transducable_JJ 
          lac_NN Z_NNP (_( β-galactosidase_JJ )_) gene_NN
          (_( Ad_NN 5_CD ._. CMV-LacZ_NNP )_) (_( Qbiogene_NNP ,_, Montreal_NNP ,_, Canada_NNP )_) ._. The_DT
          extremely_RB tight_JJ interaction_NN between_IN the_DT protein_NN
          (_( strept_NN )_) avidin_NN and_CC its_PRP$ ligand_NN biotin_NN (_( 
          K_NNP 
          d_SYM ~_NN 10_CD -_: 14_CD M_NNP )_) [_NN 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN was_VBD chosen_VBN
          as_IN a_DT means_NN of_IN tethering_VBG viral_JJ particles_NNS to_TO the_DT solid_JJ
          surface_NN ._. We_PRP previously_RB showed_VBD that_IN biotin_NN moieties_NNS can_MD be_VB
          attached_VBN covalently_RB to_TO the_DT outer_JJ surface_NN of_IN adenoviral_NN
          vectors_NNS without_IN appreciable_JJ effect_NN on_IN their_PRP$ infectivity_NN
          under_IN carefully_RB controlled_VBN biotinylation_NN conditions_NNS [_NN 10_CD
          11_CD ]_NN ._. Such_JJ biotinylated_JJ viral_JJ particles_NNS could_MD be_VB
          attached_VBN ,_, specifically_RB and_CC stably_RB ,_, to_TO a_DT solid_JJ surface_NN on_IN
          which_WDT (_( strept_NN )_) avidin_NN is_VBZ covalently_RB immobilized_JJ (_( avidin-_NN
          or_CC streptavidin-coated_JJ solid_JJ surface_NN )_) ._.
          Biotinylation_NNP of_IN Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD performed_VBN by_IN using_VBG
          sulfo-_NN NHS-LC-biotin_NNP (_( Pierce_NNP Chemical_NNP ,_, Rockford_NNP ,_, IL_NNP )_) ,_, a_DT
          biotin_NN derivative_JJ containing_VBG an_DT 
          N_NNP -_: hydroxysuccinimidyl_NN ester_NN (_( NHS_NNP )_)
          that_WDT reacts_VBZ with_IN primary_JJ amino_JJ groups_NNS ._. Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD
          treated_VBN at_IN varying_VBG concentrations_NNS (_( 0_CD -_: 100_CD μg_NN /_NN ml_NN )_) of_IN
          sulfo-_NN NHS-LC-biotin_NNP on_IN ice_NN for_IN 2_CD h_NN in_IN PBS_NNP (_( pH_NN 7_CD ._. 4_LS )_) ,_,
          followed_VBN by_IN the_DT removal_NN of_IN non-virion-associated_JJ
          biotinylation_NN reagent_NN by_IN ultrafiltration_NN ._. The_DT
          infectivities_NNS of_IN the_DT resulting_VBG adenoviral_NN vectors_NNS were_VBD
          analyzed_VBN by_IN using_VBG D-_NNP 17_CD cells_NNS [_NN canine_JJ osteosarcoma_NN cell_NN
          line_NN ;_: American_NNP Type_NNP Culture_NNP Collection_NNP (_( ATCC_NNP )_) ,_, Manassas_NNP ,_,
          VA_NNP ]_NN (_( highly_RB permissive_JJ to_TO adenoviral_NN infection_NN )_) [_NN 10_CD ]_NN as_IN
          targets_NNS ._. Little_JJ effect_NN on_IN viral_JJ infectivity_NN was_VBD seen_VBN when_WRB
          the_DT adenoviral_NN vectors_NNS were_VBD treated_VBN with_IN
          sulfo-_NN NHS-LC-biotin_NNP at_IN concentrations_NNS up_IN to_TO approximately_RB
          40_CD μg_NN /_NN ml_NN (_( data_NNS not_RB shown_VBN )_) ._. This_DT is_VBZ in_IN agreement_NN with_IN our_PRP$
          earlier_JJR study_NN [_NN 10_CD ]_NN ._.
          These_DT biotinylated_JJ adenoviral_NN vectors_NNS were_VBD analyzed_VBN
          for_IN their_PRP$ ability_NN to_TO infect_NN cells_NNS when_WRB immobilized_JJ on_IN
          streptavidin-coated_JJ solid_JJ surfaces_VBZ ._. Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD
          treated_VBN with_IN varying_VBG concentrations_NNS (_( 0_CD -_: 30_CD μg_NN /_NN ml_NN )_) of_IN
          sulfo-_NN NHS-LC-biotin_NNP ,_, and_CC non-virion-associated_JJ
          biotinylation_NN reagent_NN was_VBD removed_VBN by_IN repeated_VBN
          ultrafiltration_NN ._. The_DT resulting_VBG biotinylated_JJ adenoviral_NN
          vectors_NNS were_VBD incubated_JJ at_IN 25_CD °_NN C_NNP for_IN 2_CD h_NN with_IN gentle_JJ
          shaking_VBG in_IN polystyrene_NN wells_NNS ,_, on_IN which_WDT streptavidin_NN is_VBZ
          covalently_RB immobilized_JJ (_( well_RB diameter_NN ,_, 0_CD ._. 64_CD cm_NN ;_:
          Reacti-_NNP Bind_NNP Streptavidin_NNP Coated_NNP Polystyrene_NNP Strip_NNP Plates_NNP ;_:
          Pierce_NNP Chemical_NNP )_) (_( 5_CD ×_NN 10_CD 6_CD viral_JJ particles_NNS per_IN well_RB )_) ._. The_DT
          wells_NNS were_VBD washed_VBN to_TO remove_VB unbound_NN viral_JJ particles_NNS ,_, and_CC
          D-_NNP 17_CD cells_NNS were_VBD placed_VBN directly_RB in_IN the_DT wells_NNS (_( 8_CD ×_NN 10_CD
          3_CD cells_NNS per_IN well_RB )_) and_CC cultured_JJ at_IN 37_CD °_NN C_NNP for_IN 48_CD h_NN ,_, followed_VBN
          by_IN the_DT analysis_NN of_IN the_DT expression_NN of_IN the_DT 
          lac_NN Z_NNP gene_NN (_( Fig_NNP ._. 1_LS )_) ._. When_WRB
          Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD treated_VBN with_IN sulfo-_NN NHS-LC-biotin_NNP at_IN a_DT
          concentration_NN of_IN 0_CD ._. 6_CD μg_NN /_NN ml_NN or_CC lower_RBR ,_, almost_RB no_DT infection_NN
          of_IN D-_NNP 17_CD cells_NNS was_VBD seen_VBN ._. In_IN contrast_NN ,_, substantial_JJ numbers_NNS
          of_IN D-_NNP 17_CD cells_NNS were_VBD transduced_JJ when_WRB Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD
          treated_VBN with_IN 3_CD -_: 30_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP ._. The_DT
          maximum_NN infectivity_NN was_VBD seen_VBN with_IN Ad_NN 5_CD ._. CMV-LacZ_NNP that_WDT had_VBD
          been_VBN treated_VBN with_IN 15_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP ,_, where_WRB the_DT
          infectivity_NN was_VBD approximately_RB 75_CD %_NN of_IN that_DT of_IN unmodified_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP used_VBD free_JJ in_IN solution_NN ._. These_DT results_NNS suggest_VBP
          that_IN ,_, upon_IN biotinylation_NN of_IN the_DT viral_JJ surface_NN under_IN
          controlled_VBN conditions_NNS ,_, adenoviral_NN vectors_NNS can_MD be_VB
          immobilized_JJ on_IN a_DT solid_JJ surface_NN by_IN using_VBG the_DT
          (_( strept_NN )_) avidin-biotin_JJ interaction_NN ,_, and_CC that_IN such_JJ
          immobilized_JJ adenoviral_NN vectors_NNS are_VBP capable_JJ of_IN infecting_VBG
          cells_NNS ,_, 
          in_IN situ_NN ,_, on_IN the_DT solid_JJ surface_NN ._.
        
        
          Efficiency_NNP of_IN immobilization_NN of_IN biotinylated_JJ
          adenoviral_NN vectors_NNS
          Biotinylated_NNP Ad_NNP 5_CD ._. CMV-LacZ_NNP ,_, which_WDT had_VBD been_VBN treated_VBN with_IN
          15_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP followed_VBN by_IN the_DT removal_NN of_IN
          unreacted_JJ biotinylated_JJ reagent_NN ,_, was_VBD used_VBN to_TO determine_VB the_DT
          immobilization_NN efficiency_NN of_IN biotinylated_JJ adenoviral_NN
          vectors_NNS in_IN streptavidin-coated_JJ wells_NNS ._. Known_VBN numbers_NNS of_IN
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP particles_NNS were_VBD incubated_JJ in_IN
          streptavidin-coated_JJ wells_NNS for_IN immobilization_NN ,_, and_CC the_DT
          number_NN of_IN viral_JJ particles_NNS remaining_VBG unbound_NN in_IN the_DT
          solution_NN was_VBD estimated_VBN from_IN their_PRP$ infectivity_NN on_IN D-_NNP 17_CD
          cells_NNS (_( Fig_NNP ._. 2_LS A_DT )_) ._. Despite_IN the_DT extremely_RB tight_JJ
          streptavidin-biotin_JJ interaction_NN ,_, only_RB about_IN 15_CD -_: 40_CD %_NN of_IN
          viral_JJ particles_NNS were_VBD bound_VBN to_TO the_DT surface_NN of_IN
          streptavidin-coated_JJ wells_NNS under_IN the_DT conditions_NNS used_VBN where_WRB
          the_DT number_NN of_IN viral_JJ particles_NNS applied_VBN was_VBD considerably_RB
          below_IN saturation_NN of_IN the_DT well_NN surface_NN (_( estimated_VBN by_IN both_DT
          dimensional_NN and_CC biotin-binding_JJ capacities_NNS of_IN each_DT well_RB )_) ._.
          This_DT result_NN is_VBZ in_IN contrast_NN with_IN our_PRP$ previous_JJ study_NN ,_, which_WDT
          showed_VBD that_IN greater_JJR than_IN 95_CD %_NN of_IN biotinylated_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, prepared_VBN under_IN the_DT same_JJ conditions_NNS ,_, can_MD be_VB
          readily_RB captured_VBN on_IN streptavidin-coated_JJ microbeads_NNS [_NN 10_CD ]_NN
          ._. Thus_RB ,_, the_DT relatively_RB low_JJ immobilization_NN efficiency_NN of_IN
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP on_IN the_DT surface_NN of_IN
          streptavidin-coated_JJ wells_NNS is_VBZ not_RB attributable_JJ to_TO the_DT
          absence_NN of_IN accessible_JJ biotin_NN moieties_NNS on_IN the_DT surfaces_VBZ of_IN
          a_DT fraction_NN of_IN viral_JJ particles_NNS or_CC the_DT presence_NN of_IN
          unreacted_JJ biotinylation_NN reagent_NN in_IN the_DT biotinylated_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP preparations_NNS ._. We_PRP hypothesized_VBN that_IN the_DT
          reduction_NN of_IN the_DT immobilization_NN efficiency_NN is_VBZ caused_VBN by_IN
          physical_JJ or_CC fluidic_JJ properties_NNS of_IN viral_JJ vectors_NNS in_IN wells_NNS ,_,
          in_IN which_WDT viral_JJ particles_NNS may_MD have_VB a_DT limited_JJ ability_NN to_TO
          migrate_VB ._. To_TO test_VB this_DT ,_, a_DT constant_JJ number_NN of_IN fresh_JJ
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD applied_VBN to_TO the_DT same_JJ
          streptavidin-coated_JJ well_RB repeatedly_RB (_( 2_CD ._. 5_LS ×_NN 10_CD 6_CD viral_JJ
          particles_NNS per_IN well_RB per_IN addition_NN )_) ,_, with_IN the_DT removal_NN of_IN
          unbound_NN viral_JJ particles_NNS between_IN the_DT additions_NNS ._. The_DT
          efficiency_NN of_IN immobilization_NN at_IN each_DT addition_NN cycle_NN was_VBD
          determined_VBN from_IN the_DT number_NN of_IN viral_JJ particles_NNS remaining_VBG
          unbound_NN in_IN the_DT solution_NN (_( Fig_NNP ._. 2_LS B_NNP )_) ._. A_DT relatively_RB constant_JJ
          number_NN of_IN viral_JJ particles_NNS was_VBD bound_VBN to_TO the_DT well_NN surface_NN
          at_IN each_DT addition_NN cycle_NN of_IN biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP ._. This_DT
          means_VBZ that_IN the_DT total_JJ number_NN of_IN viral_JJ particles_NNS that_WDT were_VBD
          immobilized_JJ on_IN the_DT well_NN surface_NN increased_VBD roughly_RB
          proportionally_RB to_TO the_DT number_NN of_IN the_DT addition_NN cycle_NN of_IN
          biotinylated_JJ adenoviral_NN particles_NNS ._. This_DT result_NN suggests_VBZ
          that_IN the_DT relatively_RB low_JJ efficiency_NN of_IN immobilization_NN of_IN
          biotinylated_JJ adenoviral_NN vectors_NNS is_VBZ caused_VBN by_IN their_PRP$
          fluidic_JJ properties_NNS in_IN wells_NNS ,_, which_WDT allow_VBP only_RB a_DT fraction_NN
          of_IN viral_JJ particles_NNS to_TO reach_VB the_DT well_NN surface_NN and_CC be_VB
          captured_VBN by_IN streptavidin_NN molecules_NNS on_IN the_DT well_NN
          surface_NN ._.
        
        
          Infectivity_NNP of_IN immobilized_JJ adenoviral_NN
          vectors_NNS
          The_DT efficiency_NN of_IN 
          in_IN situ_NN transduction_NN by_IN adenoviral_NN
          vectors_NNS ,_, immobilized_JJ on_IN streptavidin-coated_JJ wells_NNS ,_, was_VBD
          investigated_VBN ._. Varying_JJ numbers_NNS of_IN biotinylated_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP (_( 2_CD ._. 5_LS ×_NN 10_CD 5_CD -_: 2_CD ._. 5_CD ×_NN 10_CD 8_CD viral_JJ particles_NNS per_IN
          well_RB )_) were_VBD added_VBN to_TO streptavidin-coated_JJ wells_NNS (_( well_RB
          diameter_NN ,_, 0_CD ._. 64_CD cm_NN )_) for_IN immobilization_NN ,_, followed_VBN by_IN the_DT
          removal_NN of_IN unbound_NN viral_JJ particles_NNS ._. D-_NNP 17_CD cells_NNS were_VBD
          placed_VBN in_IN these_DT virus-coated_JJ wells_NNS (_( 8_CD ×_NN 10_CD 2_CD cells_NNS per_IN
          well_RB )_) and_CC cultured_JJ at_IN 37_CD °_NN C_NNP for_IN 48_CD h_NN ._. Then_RB ,_, the_DT infection_NN
          of_IN the_DT cells_NNS was_VBD analyzed_VBN through_IN the_DT expression_NN of_IN the_DT 
          lac_NN Z_NNP gene_NN ._. For_IN comparison_NN ,_, the_DT
          same_JJ numbers_NNS of_IN unmodified_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP were_VBD used_VBN free_JJ in_IN
          solution_NN ._. The_DT amount_NN of_IN infection_NN increased_VBD with_IN the_DT
          increase_NN in_IN the_DT number_NN of_IN viral_JJ particles_NNS that_WDT were_VBD added_VBN
          to_TO the_DT wells_NNS at_IN the_DT immobilization_NN step_NN (_( Fig_NNP ._. 3_LS )_) ._.
          However_RB ,_, the_DT amount_NN of_IN infection_NN plateaued_JJ when_WRB 2_CD ._. 5_CD ×_NN 10_CD
          7_CD viral_JJ particles_NNS were_VBD added_VBN to_TO the_DT well_NN ._. Thus_RB ,_, when_WRB this_DT
          number_NN or_CC greater_JJR of_IN viral_JJ particles_NNS was_VBD added_VBN to_TO the_DT
          well_NN at_IN the_DT immobilization_NN step_NN ,_, all_DT of_IN the_DT cells_NNS that_WDT
          had_VBD been_VBN applied_VBN onto_IN the_DT virus-coated_JJ solid_JJ surface_NN were_VBD
          transduced_JJ ._. When_WRB unmodified_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD used_VBN free_JJ in_IN
          solution_NN ,_, the_DT saturation_NN of_IN infection_NN was_VBD seen_VBN at_IN 5_CD ×_NN 10_CD
          6_CD viral_JJ particles_NNS per_IN well_RB ._. Up_IN to_TO this_DT number_NN of_IN viral_JJ
          particles_NNS per_IN well_RB ,_, used_VBN for_IN immobilization_NN for_IN
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP or_CC for_IN transduction_NN by_IN free_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP in_IN solution_NN ,_, immobilized_JJ adenoviral_NN vectors_NNS
          showed_VBD lower_JJR infectivity_NN than_IN free_JJ viral_JJ vectors_NNS ._.
          However_RB ,_, as_IN shown_VBN in_IN Fig_NNP ._. 2_LS above_IN ,_, only_RB about_IN 15_CD -_: 40_CD %_NN of_IN
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP applied_VBD can_MD actually_RB be_VB
          immobilized_JJ on_IN streptavidin-coated_JJ wells_NNS ._. Thus_RB ,_, if_IN the_DT
          infectivity_NN is_VBZ compared_VBN using_VBG the_DT actual_JJ number_NN of_IN viral_JJ
          particles_NNS present_JJ in_IN each_DT well_RB ,_, Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, immobilized_JJ
          on_IN streptavidin-coated_JJ wells_NNS ,_, may_MD possess_VB an_DT infectivity_NN
          equivalent_JJ to_TO that_DT of_IN free_JJ adenoviral_NN vectors_NNS ._.
          We_PRP next_RB investigated_VBN how_WRB the_DT infection_NN of_IN target_NN cells_NNS
          by_IN immobilized_JJ adenoviral_NN vectors_NNS on_IN the_DT solid_JJ surface_NN is_VBZ
          affected_VBN by_IN the_DT natural_JJ permissivity_NN of_IN target_NN cells_NNS for_IN
          adenoviral_NN infection_NN ,_, determined_VBN by_IN using_VBG free_JJ adenoviral_NN
          vectors_NNS in_IN solution_NN ._. Varying_JJ numbers_NNS of_IN biotinylated_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, prepared_VBN by_IN treatment_NN with_IN 15_CD μg_NN /_NN ml_NN
          sulfo-_NN NHS-LC-biotin_NNP ,_, were_VBD applied_VBN to_TO streptavidin-coated_JJ
          wells_NNS (_( well_RB diameter_NN ,_, 0_CD ._. 64_CD cm_NN )_) for_IN immobilization_NN ,_,
          followed_VBN by_IN the_DT removal_NN of_IN unbound_NN viral_JJ particles_NNS ._.
          Target_NNP cells_NNS (_( 8_CD ×_NN 10_CD 3_CD per_IN well_RB )_) were_VBD cultured_JJ directly_RB on_IN
          the_DT virus-coated_JJ wells_NNS at_IN 37_CD °_NN C_NNP for_IN 48_CD h_NN ,_, followed_VBN by_IN the_DT
          detection_NN of_IN the_DT expression_NN of_IN the_DT 
          lac_NN Z_NNP gene_NN ._. Unmodified_NNP Ad_NNP 5_CD ._. CMV-LacZ_NNP
          were_VBD used_VBN free_JJ in_IN solution_NN for_IN comparison_NN ._. Two_CD cell_NN lines_NNS
          were_VBD used_VBN as_IN targets_NNS ._. One_CD cell_NN line_NN is_VBZ D-_NNP 17_CD ,_, which_WDT is_VBZ
          highly_RB permissive_JJ to_TO adenoviral_NN infection_NN when_WRB viral_JJ
          vectors_NNS are_VBP used_VBN free_JJ in_IN solution_NN [_NN 10_CD ]_NN ._. The_DT other_JJ cell_NN
          line_NN is_VBZ C_NNP 6_CD (_( rat_NN glioma_NN cells_NNS )_) ,_, which_WDT is_VBZ less_RBR permissive_JJ
          to_TO adenoviral_NN infection_NN [_NN 10_CD ]_NN ._. For_IN D-_NNP 17_CD cells_NNS ,_, the_DT
          amount_NN of_IN infection_NN increased_VBD steeply_RB when_WRB the_DT number_NN of_IN
          viral_JJ particles_NNS added_VBD to_TO each_DT well_RB increased_VBN from_IN 2_CD ._. 5_CD ×_NN
          10_CD 5_CD to_TO 2_CD ._. 5_CD ×_NN 10_CD 6_CD (_( Fig_NNP ._. 4_LS A_DT )_) for_IN both_DT immobilized_JJ and_CC free_JJ
          adenoviral_NN vectors_NNS ,_, although_IN free_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP showed_VBD
          higher_JJR infectivity_NN than_IN immobilized_JJ adenoviral_NN vectors_NNS ._.
          This_DT result_NN is_VBZ consistent_JJ with_IN that_DT shown_VBN in_IN Fig_NNP ._. 3_LS ._. For_IN
          C_NNP 6_CD cells_NNS ,_, no_DT appreciable_JJ infection_NN was_VBD seen_VBN with_IN free_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP even_RB when_WRB 2_CD ._. 5_CD ×_NN 10_CD 7_CD viral_JJ particles_NNS were_VBD
          used_VBN per_IN well_RB (_( Fig_NNP ._. 4_LS B_NNP )_) ._. In_IN contrast_NN ,_, when_WRB C_NNP 6_CD cells_NNS were_VBD
          cultured_JJ directly_RB on_IN streptavidin-coated_JJ wells_NNS ,_, on_IN which_WDT
          Ad_NN 5_CD ._. CMV-LacZ_NNP had_VBD been_VBN immobilized_JJ ,_, considerable_JJ amounts_NNS
          of_IN infection_NN were_VBD seen_VBN when_WRB 2_CD ._. 5_CD ×_NN 10_CD 6_CD viral_JJ particles_NNS per_IN
          well_RB and_CC greater_JJR were_VBD added_VBN to_TO wells_NNS at_IN the_DT
          immobilization_NN step_NN ._. This_DT result_NN suggests_VBZ the_DT possibility_NN
          that_IN adenoviral_NN vectors_NNS ,_, which_WDT are_VBP immobilized_JJ on_IN a_DT solid_JJ
          surface_NN ,_, can_MD infect_NN target_NN cells_NNS that_WDT are_VBP otherwise_RB
          poorly_RB permissive_JJ to_TO infection_NN by_IN free_JJ adenoviral_NN
          vectors_NNS ._. Provided_VBN that_IN this_DT notion_NN is_VBZ correct_JJ ,_, this_DT
          enhanced_JJ infectivity_NN of_IN immobilized_JJ adenoviral_NN vectors_NNS
          for_IN poorly_RB permissive_JJ target_NN cells_NNS might_MD be_VB derived_VBN from_IN
          the_DT fact_NN that_IN target_NN cells_NNS are_VBP forced_VBN to_TO make_VB direct_JJ
          contact_NN with_IN adenoviral_NN vectors_NNS on_IN the_DT solid_JJ surface_NN ,_,
          raising_VBG the_DT local_JJ concentration_NN of_IN viral_JJ particles_NNS on_IN the_DT
          cell_NN surface_NN ._. Thus_RB ,_, unlike_IN the_DT infection_NN of_IN cells_NNS by_IN free_JJ
          adenoviral_NN vectors_NNS ,_, the_DT collision_NN of_IN viral_JJ particles_NNS with_IN
          the_DT cell_NN surface_NN and_CC the_DT amount_NN of_IN the_DT primary_JJ receptor_NN
          for_IN adenoviral_NN vectors_NNS (_( coxsackie-adenovirus_JJ receptor_NN ;_:
          CAR_NNP )_) on_IN target_NN cells_NNS might_MD not_RB serve_VB as_IN the_DT primary_JJ
          determinants_NNS for_IN the_DT permissivity_NN of_IN the_DT cells_NNS ._. However_RB ,_,
          this_DT enhanced_JJ infectivity_NN of_IN immobilized_JJ adenoviral_NN
          vectors_NNS was_VBD not_RB seen_VBN with_IN all_PDT the_DT cell_NN lines_NNS tested_VBN that_WDT
          are_VBP poorly_RB permissive_JJ to_TO adenoviral_NN infection_NN ._. For_IN
          example_NN ,_, the_DT infectivity_NN of_IN immobilized_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD
          analyzed_VBN for_IN two_CD human_JJ colon_NN adenocarcinoma_NN cell_NN lines_NNS ,_,
          HT-_NNP 29_CD (_( ATCC_NNP )_) and_CC COLO_NNP 205_CD (_( ATCC_NNP )_) ,_, which_WDT are_VBP highly_RB
          resistant_JJ to_TO adenoviral_NN infection_NN [_NN 12_CD ]_NN ._. HT-_NNP 29_CD
          expresses_VBZ only_RB a_DT small_JJ amount_NN of_IN CAR_NNP on_IN the_DT cell_NN surface_NN ._.
          Adenoviral_NNP particles_NNS can_MD be_VB taken_VBN up_RP relatively_RB
          efficiently_RB by_IN this_DT cell_NN line_NN ,_, but_CC this_DT does_VBZ not_RB result_VB
          in_IN transduction_NN of_IN cells_NNS ._. Thus_RB ,_, the_DT expression_NN of_IN
          transgenes_NNS is_VBZ extremely_RB poor_JJ [_NN 12_CD ]_NN ._. The_DT expression_NN of_IN
          CAR_NNP on_IN the_DT surface_NN of_IN COLO_NNP 205_CD cells_NNS is_VBZ even_RB lower_JJR than_IN
          HT-_NNP 29_CD cells_NNS ,_, and_CC such_JJ CAR_NNP expression_NN can_MD be_VB seen_VBN on_IN only_RB
          about_IN 50_CD %_NN of_IN COLO_NNP 205_CD cells_NNS ._. Similar_JJ to_TO HT-_NNP 29_CD cells_NNS ,_, the_DT
          transduction_NN efficiency_NN of_IN adenoviral_NN vectors_NNS for_IN COLO_NNP 205_CD
          is_VBZ extremely_RB poor_JJ [_NN 12_CD ]_NN ._. The_DT very_RB low_JJ transduction_NN
          efficiency_NN of_IN COLO_NNP 205_CD by_IN adenoviral_NN vectors_NNS ,_, used_VBD free_JJ in_IN
          solution_NN ,_, was_VBD confirmed_VBN in_IN our_PRP$ previous_JJ study_NN [_NN 10_CD ]_NN ._.
          When_WRB up_IN to_TO 2_CD ._. 5_CD ×_NN 10_CD 7_CD viral_JJ particles_NNS were_VBD added_VBN to_TO each_DT
          well_RB at_IN the_DT immobilization_NN step_NN (_( or_CC for_IN transduction_NN by_IN
          free_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP )_) ,_, the_DT infectivity_NN of_IN immobilized_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD only_RB slightly_RB higher_JJR than_IN free_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP in_IN solution_NN (_( data_NNS not_RB shown_VBN )_) ._. This_DT might_MD
          imply_VB that_IN the_DT binding_JJ of_IN viral_JJ particles_NNS to_TO CAR_NNP is_VBZ still_RB
          required_VBN for_IN the_DT 
          in_IN situ_NN infection_NN of_IN target_NN cells_NNS
          on_IN solid_JJ surfaces_VBZ by_IN immobilized_JJ adenoviral_NN vectors_NNS ._.
        
        
          Adenoviral_NNP vector_NN spots_NNS on_IN solid_JJ surfaces_VBZ
          Successful_JJ 
          in_IN situ_NN infection_NN of_IN target_NN cells_NNS
          by_IN adenoviral_NN vectors_NNS on_IN a_DT solid_JJ surface_NN ,_, shown_VBN above_IN ,_,
          suggests_VBZ that_IN this_DT technology_NN could_MD be_VB used_VBN to_TO control_VB ,_,
          spatially_RB ,_, the_DT location_NN of_IN gene_NN transduction_NN on_IN a_DT solid_JJ
          surface_NN by_IN strategic_JJ placement_NN of_IN viral_JJ vectors_NNS ._. There_EX
          are_VBP several_JJ possible_JJ ways_NNS of_IN immobilizing_VBG viral_JJ vectors_NNS
          at_IN predetermined_VBN locations_NNS on_IN the_DT solid_JJ surface_NN by_IN using_VBG
          the_DT (_( strept_NN )_) avidin-biotin_JJ interaction_NN ._. We_PRP used_VBD one_CD such_JJ
          method_NN to_TO fabricate_VB solid_JJ surfaces_VBZ with_IN adenoviral_NN
          vectors_NNS immobilized_JJ as_IN discrete_JJ spots_NNS with_IN predetermined_VBN
          sizes_NNS ._. In_IN this_DT method_NN ,_, biotin_NN moieties_NNS were_VBD initially_RB
          attached_VBN covalently_RB to_TO discrete_JJ regions_NNS on_IN a_DT solid_JJ
          surface_NN ._. To_TO the_DT biotin_NN moieties_NNS on_IN the_DT solid_JJ surface_NN ,_,
          biotinylated_JJ adenoviral_NN vectors_NNS were_VBD attached_VBN by_IN using_VBG
          avidin_NN as_IN a_DT molecular_JJ bridge_NN between_IN the_DT biotin_NN moieties_NNS
          on_IN the_DT solid_JJ surface_NN and_CC the_DT viral_JJ surface_NN ._. Cell_NNP culture_NN
          plates_NNS ,_, which_WDT are_VBP coated_VBN with_IN poly-_NN D-_NNP lysine_NN (_( well_RB
          diameter_NN ,_, 3_CD ._. 5_CD cm_NN ;_: Biocoat_NNP Poly-_NNP D-L_NNP ysine_NN Cellware_NNP 6_CD -_: Well_RB
          Plates_NNP ;_: Becton_NNP Dickinson_NNP Labware_NNP ,_, Bedford_NNP ,_, MA_NNP )_) ,_, were_VBD used_VBN
          as_IN the_DT solid_JJ surface_NN ._. Sulfo-_NNP NHS-LC-biotin_NNP was_VBD used_VBN to_TO
          attach_VB biotin_NN moieties_NNS ,_, covalently_RB ,_, to_TO the_DT primary_JJ amino_JJ
          groups_NNS of_IN poly-_NN D-_NNP lysine_NN on_IN the_DT solid_JJ surface_NN ._. During_IN the_DT
          biotinylation_NN reaction_NN ,_, plastic_NN rings_NNS (_( inner_JJ diameter_NN ,_,
          1_CD ._. 4_CD cm_NN )_) and_CC agarose_NN were_VBD used_VBN to_TO delimit_NN the_DT regions_NNS of_IN
          biotinylation_NN on_IN the_DT solid_JJ surface_NN and_CC to_TO protect_VB the_DT
          remaining_VBG areas_NNS from_IN biotinylation_NN ,_, respectively_RB ._. After_IN
          unreacted_JJ biotinylation_NN reagent_NN was_VBD removed_VBN ,_, excess_JJ
          Neutralite_NNP avidin_NN (_( a_DT deglycosylated_JJ ,_, neutralized_VBN form_NN of_IN
          avidin_NN ;_: Southern_NNP Biotechnology_NNP Associates_NNPS ,_, Alabama_NNP ,_, AL_NNP )_)
          was_VBD added_VBN ,_, which_WDT should_MD bind_NN to_TO biotin_NN moieties_NNS on_IN the_DT
          solid_JJ surface_NN ._. After_IN the_DT removal_NN of_IN unbound_NN Neutralite_NNP
          avidin_NN ,_, Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, which_WDT had_VBD been_VBN biotinylated_JJ by_IN
          treatment_NN with_IN 15_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP as_IN above_IN ,_, was_VBD
          applied_VBN to_TO the_DT wells_NNS and_CC allowed_VBN to_TO bind_NN to_TO unoccupied_JJ
          biotin-binding_JJ sites_NNS of_IN Neutralite_NNP avidin_NN that_WDT had_VBD been_VBN
          bound_VBN to_TO biotin_NN moieties_NNS on_IN the_DT solid_JJ surface_NN ._. D-_NNP 17_CD cells_NNS
          were_VBD applied_VBN to_TO the_DT entire_JJ wells_NNS (_( 2_CD ._. 5_LS ×_NN 10_CD 5_CD cells_NNS per_IN
          well_RB )_) and_CC cultured_JJ at_IN 37_CD °_NN C_NNP for_IN 48_CD h_NN ,_, followed_VBN by_IN the_DT
          detection_NN of_IN the_DT expression_NN of_IN the_DT 
          lac_NN Z_NNP gene_NN (_( Fig_NNP ._. 5_LS )_) ._. Specific_JJ
          transduction_NN of_IN target_NN cells_NNS is_VBZ seen_VBN only_RB at_IN the_DT
          locations_NNS (_( spots_NNS )_) where_WRB biotin_NN moieties_NNS were_VBD initially_RB
          attached_VBN ._. This_DT demonstrates_VBZ regio-specific_JJ 
          in_IN situ_NN transduction_NN of_IN target_NN
          cells_NNS by_IN adenoviral_NN vectors_NNS at_IN predetermined_VBN locations_NNS ._.
          Very_RB limited_JJ numbers_NNS of_IN infected_JJ cells_NNS were_VBD present_JJ
          outside_IN the_DT biotinylation_NN areas_NNS ,_, indicating_VBG that_IN
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD bound_VBN specifically_RB to_TO
          biotin_NN moieties_NNS on_IN the_DT well_NN surface_NN via_IN Neutralite_NNP
          avidin_NN ._. This_DT result_NN reveals_VBZ that_IN the_DT ultimate_JJ spatial_NN
          arrangements_NNS of_IN transduced_JJ cells_NNS on_IN a_DT solid_JJ surface_NN can_MD
          be_VB controlled_VBN and_CC predetermined_VBN at_IN the_DT time_NN of_IN the_DT
          fabrication_NN of_IN the_DT solid_JJ surface_NN ,_, during_IN which_WDT time_NN viral_JJ
          vectors_NNS can_MD be_VB attached_VBN to_TO desired_VBN locations_NNS in_IN any_DT
          shapes_NNS ,_, patterns_NNS ,_, and_CC sizes_NNS ._.
        
      
      
        Discussion_NNP
        We_PRP previously_RB reported_VBD a_DT strategy_NN similar_JJ to_TO the_DT one_CD
        described_VBD in_IN this_DT study_NN ._. In_IN this_DT strategy_NN ,_, biotinylated_JJ
        adenoviral_NN vectors_NNS are_VBP immobilized_JJ on_IN the_DT surfaces_VBZ of_IN
        streptavidin-coated_JJ microbeads_NNS with_IN diameters_NNS up_IN to_TO a_DT few_JJ
        micrometers_NNS [_NN 10_CD ]_NN ._. For_IN such_JJ adenovirus-microbead_JJ
        conjugates_NNS ,_, great_JJ enhancement_NN in_IN transduction_NN efficiency_NN
        was_VBD seen_VBN with_IN several_JJ different_JJ cell_NN lines_NNS ,_, including_VBG
        COLO_NNP 205_CD ,_, the_DT infection_NN efficiency_NN of_IN which_WDT was_VBD not_RB notably_RB
        enhanced_VBN by_IN adenoviral_NN vectors_NNS immobilized_JJ on_IN
        streptavidin-coated_JJ wells_NNS in_IN the_DT present_JJ study_NN ._. The_DT primary_JJ
        difference_NN between_IN the_DT two_CD strategies_NNS is_VBZ derived_VBN from_IN the_DT
        size_NN of_IN solid_JJ surfaces_VBZ (_( streptavidin-coated_JJ wells_NNS and_CC
        streptavidin-coated_JJ microbeads_NNS )_) relative_JJ to_TO target_VB cells_NNS ._.
        The_DT sizes_NNS of_IN adenovirus-microbead_JJ conjugates_NNS are_VBP smaller_JJR
        than_IN those_DT of_IN target_NN cells_NNS ._. Thus_RB ,_, the_DT entire_JJ
        adenovirus-microbead_JJ conjugates_NNS can_MD be_VB taken_VBN up_RP by_IN cells_NNS ._.
        Such_JJ internalization_NN events_NNS appear_VBP to_TO contribute_VB
        substantially_RB to_TO the_DT infectivity_NN enhancement_NN by_IN
        virus-microbead_JJ conjugates_NNS ._. In_IN contrast_NN ,_, the_DT dissociation_NN
        of_IN viral_JJ particles_NNS from_IN the_DT solid_JJ surface_NN must_MD occur_VB for_IN
        adenoviral_NN vectors_NNS ,_, which_WDT are_VBP initially_RB immobilized_JJ on_IN
        streptavidin-coated_JJ wells_NNS ,_, to_TO be_VB taken_VBN up_RP by_IN target_NN cells_NNS ._.
        This_DT may_MD be_VB one_CD possible_JJ explanation_NN of_IN why_WRB infectivity_NN
        enhancement_NN was_VBD seen_VBN with_IN adenovirus-microbead_JJ conjugates_NNS
        and_CC was_VBD not_RB with_IN adenoviral_NN vectors_NNS immobilized_JJ on_IN
        streptavidin-coated_JJ wells_NNS ,_, except_IN for_IN one_CD cell_NN line_NN
        (_( C_NNP 6_CD )_) ._.
        Virus-coated_NNP solid_JJ surfaces_VBZ should_MD offer_VB a_DT variety_NN of_IN
        both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN applications_NNS ._. One_CD such_JJ 
        in_IN vitro_NN application_NN would_MD be_VB the_DT
        creation_NN of_IN virus_NN arrays_NNS for_IN expression_NN and_CC functional_JJ
        analysis_NN of_IN genes_NNS [_NN 13_CD 14_CD ]_NN ._. A_DT recombinant_JJ viral_JJ vector_NN
        library_NN ,_, each_DT clone_NN of_IN which_WDT carries_VBZ a_DT different_JJ gene_NN ,_,
        could_MD be_VB immobilized_JJ in_IN an_DT ordered_VBN manner_NN as_IN discrete_JJ spots_NNS
        on_IN a_DT solid_JJ surface_NN ._. Onto_NNP the_DT resulting_VBG virus_NN array_NN ,_, target_NN
        cells_NNS are_VBP applied_VBN and_CC cultured_JJ ._. This_DT should_MD result_VB in_IN the_DT
        expression_NN of_IN encoded_JJ genes_NNS in_IN target_NN cells_NNS in_IN an_DT array_NN
        format_NN ,_, in_IN which_WDT each_DT encoded_JJ gene_NN should_MD be_VB expressed_VBN in_IN a_DT
        discrete_JJ cell_NN spot_NN while_IN maintaining_VBG the_DT original_JJ location_NN
        of_IN the_DT viral_JJ vector_NN spot_NN in_IN the_DT virus_NN array_NN ._. Thus_RB ,_,
        expression_NN and_CC functional_JJ analysis_NN of_IN many_JJ different_JJ genes_NNS
        can_MD potentially_RB be_VB performed_VBN with_IN a_DT single_JJ virus_NN array_NN for_IN
        a_DT given_VBN target_NN cell_NN line_NN ._. The_DT use_NN of_IN viral_JJ vectors_NNS should_MD
        offer_VB enhanced_VBD efficiencies_NNS and_CC versatility_NN for_IN the_DT
        expression_NN of_IN cloned_VBN genes_NNS in_IN various_JJ cell_NN types_NNS than_IN
        approaches_NNS using_VBG expression_NN plasmids_NNS that_WDT are_VBP printed_VBN on_IN
        solid_JJ surfaces_VBZ [_NN 15_CD 16_CD ]_NN ._. This_DT might_MD be_VB particularly_RB true_JJ
        to_TO primary_JJ cells_NNS ,_, which_WDT often_RB show_NN poor_JJ expression_NN of_IN
        encoded_JJ genes_NNS when_WRB plasmid-based_JJ expression_NN vectors_NNS are_VBP
        used_VBN ._. The_DT availability_NN of_IN such_JJ viral_JJ vector_NN libraries_NNS ,_,
        particularly_RB those_DT based_VBN on_IN adenoviral_NN vectors_NNS [_NN 17_CD 18_CD ]_NN ,_,
        should_MD facilitate_VB the_DT realization_NN of_IN such_JJ applications_NNS ._.
        Virus-coated_NNP solid_JJ surfaces_VBZ could_MD also_RB be_VB used_VBN for_IN 
        in_IN vitro_NN tissue_NN engineering_NN
        applications_NNS ,_, for_IN which_WDT the_DT shapes_NNS and_CC sizes_NNS of_IN
        areas_NNS /_NN regions_NNS of_IN genetically_RB engineered_VBN cells_NNS can_MD be_VB
        predetermined_VBN two-dimensionally_JJ by_IN strategic_JJ placement_NN and_CC
        patterning_VBG of_IN viral_JJ vectors_NNS on_IN solid_JJ surfaces_VBZ ,_, as_IN
        exemplified_VBN in_IN Fig_NNP ._. 5_LS ._. Such_JJ precise_JJ control_NN of_IN the_DT shapes_NNS
        and_CC sizes_NNS of_IN areas_NNS /_NN regions_NNS of_IN genetically_RB engineered_VBN cells_NNS
        would_MD be_VB very_RB difficult_JJ to_TO achieve_VB with_IN free_JJ viral_JJ vectors_NNS ,_,
        which_WDT can_MD diffuse_NN freely_RB in_IN solution_NN ._.
        Virus-coated_NNP solid_JJ surfaces_VBZ could_MD also_RB be_VB used_VBN 
        in_IN vivo_NN for_IN highly_RB site-specific_JJ
        delivery_NN of_IN viral_JJ particles_NNS to_TO target_VB tissues_NNS or_CC cells_NNS
        through_IN the_DT direct_JJ application_NN of_IN virus-coated_JJ solid_JJ
        surfaces_VBZ to_TO target_VB sites_NNS ._. The_DT delivery_NN of_IN viral_JJ vectors_NNS in_IN
        a_DT solid-surface-associated_JJ form_NN should_MD eliminate_VB the_DT
        migration_NN of_IN viral_JJ particles_NNS from_IN the_DT administration_NN site_NN ,_,
        minimizing_VBG uncontrolled_JJ transduction_NN of_IN non-target_JJ tissues_NNS ._.
        For_IN example_NN ,_, a_DT virus-coated_JJ solid_JJ surface_NN ,_, the_DT size_NN of_IN
        which_WDT has_VBZ been_VBN adjusted_VBN to_TO the_DT intended_VBN transduction_NN site_NN ,_,
        could_MD be_VB transplanted_VBN into_IN a_DT target_NN tissue_NN ,_, allowing_VBG the_DT
        specific_JJ transduction_NN of_IN the_DT target_NN site_NN by_IN immobilized_JJ
        viral_JJ vectors_NNS with_IN minimal_JJ infection_NN of_IN surrounding_VBG
        tissues_NNS ._. As_IN proposed_VBN for_IN 
        in_IN vitro_NN applications_NNS described_VBD
        above_IN ,_, the_DT primary_JJ advantage_NN for_IN such_JJ 
        in_IN vivo_NN gene_NN transfer_NN applications_NNS
        would_MD be_VB that_IN the_DT shapes_NNS and_CC sizes_NNS of_IN areas_NNS /_NN regions_NNS of_IN
        transduction_NN sites_NNS can_MD be_VB predetermined_VBN by_IN strategic_JJ
        placement_NN and_CC patterning_VBG of_IN viral_JJ vectors_NNS on_IN solid_JJ
        surfaces_VBZ ._.
      
      
        Conclusions_NNP
        We_PRP have_VBP devised_VBN a_DT method_NN of_IN immobilizing_VBG adenoviral_NN
        vectors_NNS ,_, tightly_RB and_CC stably_RB ,_, on_IN solid_JJ surfaces_VBZ using_VBG the_DT
        (_( strept_NN )_) avidin-biotin_JJ interaction_NN ,_, while_IN maintaining_VBG their_PRP$
        ability_NN to_TO infect_NN cells_NNS ._. Such_JJ immobilized_JJ viral_JJ vectors_NNS can_MD
        infect_NN target_NN cells_NNS ,_, 
        in_IN situ_NN ,_, on_IN solid_JJ surfaces_VBZ with_IN
        efficiencies_NNS equivalent_JJ to_TO the_DT same_JJ viral_JJ vectors_NNS used_VBD free_JJ
        in_IN solution_NN for_IN the_DT cell_NN lines_NNS tested_VBN ._. For_IN one_CD cell_NN line_NN
        (_( C_NNP 6_CD )_) ,_, the_DT infection_NN efficiency_NN by_IN immobilized_JJ viral_JJ vectors_NNS
        was_VBD greater_JJR than_IN the_DT same_JJ viral_JJ vectors_NNS used_VBD free_JJ in_IN
        solution_NN ,_, which_WDT showed_VBD a_DT limited_JJ ability_NN to_TO infect_NN the_DT
        target_NN cells_NNS ._. This_DT strategy_NN should_MD be_VB very_RB useful_JJ for_IN the_DT
        development_NN of_IN a_DT variety_NN of_IN both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN applications_NNS ,_, including_VBG the_DT
        creation_NN of_IN cell-based_JJ expression_NN arrays_NNS for_IN proteomics_NNS and_CC
        drug_NN discovery_NN and_CC highly_RB site-specific_JJ delivery_NN of_IN
        transgenes_NNS for_IN gene_NN therapy_NN and_CC tissue_NN engineering_NN ._.
      
      
        Methods_NNP
        
          Adenoviral_NNP vectors_NNS
          The_DT recombinant_JJ adenoviral_NN vectors_NNS used_VBN are_VBP
          Ad_NN 5_CD ._. CMV-LacZ_NNP (_( Qbiogene_NNP )_) ,_, which_WDT is_VBZ derived_VBN from_IN adenovirus_JJ
          serotype_NN 5_CD with_IN the_DT deletion_NN of_IN the_DT viral_JJ E_NNP 1_CD A_DT ,_, E_NN 1_CD B_NNP ,_, and_CC
          E_NNP 3_CD genes_NNS ._. Ad_NN 5_CD ._. CMV-LacZ_NNP carries_VBZ the_DT bacterial_JJ 
          lac_NN Z_NNP (_( β-galactosidase_JJ )_) gene_NN under_IN
          the_DT control_NN of_IN the_DT human_JJ cytomegalovirus_JJ (_( CMV_NNP )_)
          immediate-early_JJ promoter_NN with_IN the_DT human_JJ β-globin_JJ
          polyadenylation_NN signal_NN sequence_NN ._. This_DT viral_JJ vector_NN had_VBD
          been_VBN purified_JJ by_IN two_CD rounds_NNS of_IN CsCl_NNP gradient_NN
          centrifugation_NN ._.
        
        
          Target_NNP cells_NNS
          The_DT following_VBG two_CD cell_NN lines_NNS were_VBD used_VBN as_IN targets_NNS for_IN
          adenoviral_NN infection_NN :_: D-_NNP 17_CD (_( canine_JJ osteosarcoma_NN cells_NNS )_)
          and_CC C_NNP 6_CD (_( rat_NN glioma_NN cells_NNS )_) ,_, both_DT of_IN which_WDT were_VBD obtained_VBN
          from_IN ATCC_NNP ._. These_DT cell_NN lines_NNS were_VBD grown_VBN at_IN 37_CD °_NN C_NNP in_IN a_DT
          humidified_JJ atmosphere_NN containing_VBG 5_CD %_NN CO_NNP 
          2_CD ._. D-_NNP 17_CD cells_NNS were_VBD maintained_VBN in_IN
          Dulbecco_NNP 's_POS modified_VBN Eagles_NNPS medium_NN (_( DMEM_NNP ;_: BioWhittaker_NNP )_)
          supplemented_JJ with_IN 6_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP ;_:
          BioWhittaker_NNP )_) ,_, and_CC C_NNP 6_CD cells_NNS were_VBD in_IN DMEM_NNP supplemented_JJ
          with_IN 10_CD %_NN FBS_NNP ._.
        
        
          Biotinylation_NNP of_IN adenoviral_NN vectors_NNS with_IN
          sulfo-_NN NHS-LC-biotin_NNP
          Sulfo-_NNP NHS-LC-biotin_NNP (_( Pierce_NNP Chemical_NNP )_) was_VBD dissolved_VBN in_IN
          dimethylformamide_NN at_IN a_DT concentration_NN of_IN 3_CD mg_NN /_NN ml_NN and_CC added_VBD
          to_TO Ad_NN 5_CD ._. CMV-LacZ_NNP [_NN 1_CD ._. 0_CD ×_NN 10_CD 9_CD viral_JJ particles_NNS in_IN 100_CD μl_NN PBS_NNP
          (_( pH_NN 7_CD ._. 4_LS )_) ]_NN to_TO various_JJ final_JJ concentrations_NNS (_( 0_CD -_: 100_CD
          μg_NN /_NN ml_NN )_) ._. The_DT reaction_NN mixtures_NNS were_VBD incubated_JJ on_IN ice_NN in_IN
          the_DT dark_NN for_IN 2_CD h_NN ,_, and_CC the_DT biotinylation_NN reaction_NN was_VBD
          terminated_VBN by_IN the_DT addition_NN of_IN 100_CD μl_NN of_IN 9_CD mM_NN glycine_NN in_IN
          PBS_NNP (_( pH_NN 7_CD ._. 4_LS )_) ._. The_DT viral_JJ particles_NNS were_VBD subjected_VBN to_TO three_CD
          rounds_NNS of_IN ultrafiltration_NN with_IN ZM-_NNP 500_CD centrifugal_JJ
          filtration_NN units_NNS (_( molecular_JJ mass_NN cut-off_JJ ,_, 500_CD kDa_NN ;_:
          Millipore_NNP )_) using_VBG PBS_NNP (_( pH_NN 7_CD ._. 4_LS )_) containing_VBG 0_CD ._. 05_CD %_NN Tween_NNP 20_CD
          (_( PBST_NNP )_) as_IN a_DT diluent_NN to_TO remove_VB non-virion-associated_JJ
          biotinylation_NN reagent_NN ._. Finally_RB ,_, the_DT viral_JJ particles_NNS were_VBD
          suspended_VBN in_IN 100_CD μl_NN of_IN fresh_JJ PBST_NNP at_IN a_DT concentration_NN of_IN 1_CD
          ×_NN 10_CD 10_CD viral_JJ particles_NNS /_NN ml_NN ._.
          For_IN the_DT infectivity_NN analysis_NN of_IN biotinylated_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, dilutions_NNS of_IN biotinylated_JJ viral_JJ vectors_NNS
          were_VBD placed_VBN over_IN monolayers_NNS of_IN D-_NNP 17_CD target_NN cells_NNS on_IN a_DT
          96_CD -_: well_RB cell_NN culture_NN plate_NN (_( 8_CD ×_NN 10_CD 3_CD cells_NNS per_IN well_RB )_) ,_,
          followed_VBN by_IN the_DT incubation_NN of_IN cells_NNS at_IN 37_CD °_NN C_NNP for_IN 48_CD h_NN ._.
          Then_RB ,_, cells_NNS were_VBD fixed_VBN with_IN 0_CD ._. 5_CD %_NN glutaraldehyde_NN and_CC
          stained_JJ for_IN β-galactosidase_JJ (_( LacZ_NNP )_) activity_NN using_VBG
          5_CD -_: bromo-_NN 4_CD -_: chloro-_NN 3_CD -_: indoyl-β-_JJ D-_NNP galactopyronoside_NN (_( X-G_NNP al_NN )_)
          as_IN the_DT substrate_NN ._. The_DT numbers_NNS of_IN infected_JJ ,_, 
          lac_NN Z-_NNP expressing_VBG cells_NNS for_IN 10_CD -_: 15_CD
          randomly_RB chosen_VBN microscopic_JJ fields_NNS (_( 3_CD ._. 75_CD mm_NN 2_LS )_) in_IN each_DT
          well_RB were_VBD counted_VBN and_CC used_VBN to_TO assess_VB the_DT total_JJ number_NN of_IN
          infected_JJ cells_NNS in_IN each_DT well_RB ._.
        
        
          Preparation_NNP of_IN wells_NNS coated_VBN with_IN adenoviral_NN
          vectors_NNS
          Biotinylated_NNP Ad_NNP 5_CD ._. CMV-LacZ_NNP ,_, prepared_VBN by_IN treatment_NN with_IN
          15_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP as_IN above_IN ,_, was_VBD diluted_VBN in_IN
          PBST_NNP and_CC incubated_JJ for_IN immobilization_NN in_IN
          streptavidin-coated_JJ wells_NNS (_( well_RB diameter_NN ,_, 0_CD ._. 64_CD cm_NN ;_:
          Reacti-_NNP Bind_NNP Streptavidin_NNP Coated_NNP Polystyrene_NNP Wells_NNP ,_, Pierce_NNP
          Chemical_NNP )_) (_( 50_CD μl_NN per_IN well_RB )_) for_IN 2_CD h_NN at_IN 25_CD °_NN C_NNP with_IN shaking_VBG
          on_IN a_DT rotary_JJ shaker_NN at_IN 150_CD rpm_NN ._. The_DT solution_NN of_IN each_DT well_RB ,_,
          which_WDT contained_VBD unbound_NN Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, was_VBD collected_VBN and_CC
          analyzed_VBN for_IN infectivity_NN on_IN D-_NNP 17_CD cells_NNS as_IN above_IN to_TO
          estimate_VB the_DT number_NN of_IN unbound_NN viral_JJ particles_NNS ._. The_DT wells_NNS
          were_VBD washed_VBN with_IN PBST_NNP and_CC then_RB with_IN PBS_NNP (_( pH_NN 7_CD ._. 4_LS )_) without_IN
          Tween_NNP 20_CD ._. Onto_NNP the_DT wells_NNS coated_VBN with_IN biotinylated_JJ
          Ad_NN 5_CD ._. CMV-LacZ_NNP ,_, target_NN cells_NNS were_VBD placed_VBN and_CC cultured_JJ at_IN
          37_CD °_NN C_NNP for_IN 48_CD h_NN ._. Cells_NNP were_VBD fixed_VBN with_IN glutaraldehyde_NN and_CC
          stained_JJ for_IN the_DT expression_NN of_IN the_DT 
          lac_NN Z_NNP gene_NN as_IN described_VBN above_IN ._. For_IN
          control_NN experiments_NNS ,_, a_DT solution_NN containing_VBG free_JJ ,_,
          unmodified_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP (_( 50_CD μl_NN per_IN well_RB )_) was_VBD applied_VBN to_TO
          target_VB cells_NNS grown_VBN on_IN streptavidin-coated_JJ wells_NNS ._.
        
        
          Repeated_NNP application_NN of_IN biotinylated_JJ adenoviral_NN
          vectors_NNS to_TO wells_NNS
          Biotinylated_NNP Ad_NNP 5_CD ._. CMV-LacZ_NNP ,_, prepared_VBN by_IN treatment_NN with_IN
          15_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP as_IN above_IN ,_, was_VBD diluted_VBN in_IN
          PBST_NNP and_CC added_VBD to_TO streptavidin-coated_JJ wells_NNS (_( 2_CD ._. 5_LS ×_NN 10_CD
          6_CD viral_JJ particles_NNS in_IN 50_CD μl_NN PBST_NNP per_IN well_RB )_) and_CC incubated_JJ
          with_IN shaking_VBG on_IN a_DT rotary_JJ shaker_NN at_IN 150_CD nm_NN at_IN 25_CD °_NN C_NNP for_IN 30_CD
          min_NN ._. The_DT solution_NN in_IN each_DT well_RB ,_, which_WDT contained_VBD unbound_NN
          viral_JJ particles_NNS ,_, was_VBD collected_VBN ,_, and_CC the_DT wells_NNS were_VBD washed_VBN
          three_CD times_NNS with_IN PBST_NNP ._. Then_RB ,_, the_DT same_JJ number_NN of_IN fresh_JJ
          biotinylated_JJ Ad_NN 5_CD ._. CMV-LacZ_NNP was_VBD added_VBN to_TO the_DT well_NN and_CC
          incubated_JJ in_IN the_DT same_JJ manner_NN ,_, followed_VBN by_IN the_DT collection_NN
          of_IN unbound_NN viral_JJ particles_NNS and_CC washing_NN of_IN the_DT wells_NNS ._.
          These_DT steps_NNS were_VBD repeated_VBN several_JJ more_JJR times_NNS ._. The_DT unbound_NN
          viral_JJ particle_NN fraction_NN ,_, collected_VBN after_IN each_DT addition_NN
          cycle_NN ,_, was_VBD subjected_VBN to_TO infectivity_NN analysis_NN on_IN D-_NNP 17_CD
          cells_NNS to_TO estimate_VB the_DT number_NN of_IN unbound_NN Ad_NN 5_CD ._. CMV-LacZ_NNP ._.
        
        
          Preparation_NNP of_IN adenoviral_NN vector_NN spots_NNS on_IN solid_JJ
          surfaces_VBZ
          Six-well_NNP cell_NN culture_NN plates_NNS ,_, coated_VBN with_IN poly-_NN
          D-_NNP lysine_NN (_( well_RB diameter_NN ,_, 3_CD ._. 5_CD cm_NN ;_: Biocoat_NNP Poly-_NNP D-L_NNP ysine_NN
          Cellware_NNP 6_CD -_: Well_RB Plates_NNP ,_, Becton_NNP Dickinson_NNP Labware_NNP )_) ,_, were_VBD
          used_VBN as_IN the_DT solid_JJ surface_NN ._. First_LS ,_, spots_NNS of_IN biotin_NN
          moieties_NNS on_IN the_DT wells_NNS were_VBD created_VBN by_IN using_VBG
          sulfo-_NN NHS-LC-biotin_NNP ._. Plastic_NNP rings_NNS (_( inner_JJ diameter_NN ,_, 1_CD ._. 4_CD
          cm_NN )_) were_VBD used_VBN to_TO specify_VB the_DT biotinylation_NN areas_NNS ,_, and_CC the_DT
          remaining_VBG area_NN of_IN the_DT wells_NNS was_VBD covered_VBN with_IN a_DT layer_NN of_IN
          2_CD %_NN agarose_NN in_IN PBS_NNP ._. These_DT spot_NN areas_NNS within_IN plastic_NN rings_NNS
          were_VBD treated_VBN with_IN 1_CD mg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP in_IN PBS_NNP (_( pH_NN
          7_CD ._. 4_LS )_) (_( 50_CD μl_NN per_IN spot_NN )_) for_IN 2_CD h_NN at_IN 4_CD °_NN C_NNP and_CC then_RB washed_VBN with_IN
          PBST_NNP to_TO remove_VB unreacted_JJ biotinylation_NN reagent_NN ._.
          Neutralite_NNP avidin_NN (_( Southern_NNP Biotechnology_NNP Associates_NNPS )_) (_( 25_CD
          μg_NN in_IN 50_CD μl_NN PBST_NNP per_IN spot_NN )_) was_VBD added_VBN to_TO the_DT spot_NN areas_NNS
          within_IN plastic_NN rings_NNS ,_, which_WDT had_VBD been_VBN treated_VBN with_IN
          sulfo-_NN NHS-LC-biotin_NNP ,_, and_CC allowed_VBD to_TO bind_NN to_TO biotin_NN
          moieties_NNS on_IN the_DT well_NN surface_NN ._. Unbound_NNP Neutralite_NNP avidin_NN
          was_VBD removed_VBN by_IN washing_VBG the_DT wells_NNS with_IN PBST_NNP ._. Biotinylated_NNP
          Ad_NNP 5_CD ._. CMV-LacZ_NNP (_( 1_CD ×_NN 10_CD 7_CD viral_JJ particles_NNS per_IN spot_NN )_) ,_, prepared_VBN
          by_IN treatment_NN with_IN 15_CD μg_NN /_NN ml_NN sulfo-_NN NHS-LC-biotin_NNP as_IN above_IN ,_,
          were_VBD incubated_JJ in_IN the_DT spot_NN areas_NNS within_IN plastic_NN rings_NNS at_IN
          25_CD °_NN C_NNP for_IN 2_CD h_NN ,_, followed_VBN by_IN washing_VBG the_DT wells_NNS with_IN PBST_NNP to_TO
          remove_VB unbound_NN viral_JJ particles_NNS ._. The_DT plastic_NN rings_NNS and_CC
          agarose_NN were_VBD removed_VBN from_IN the_DT wells_NNS ,_, and_CC the_DT entire_JJ wells_NNS
          were_VBD washed_VBN with_IN PBS_NNP ._. D-_NNP 17_CD cells_NNS (_( 2_CD ._. 5_LS ×_NN 10_CD 5_CD per_IN well_RB )_)
          were_VBD applied_VBN to_TO the_DT entire_JJ wells_NNS and_CC cultured_JJ at_IN 37_CD °_NN C_NNP for_IN
          48_CD h_NN ._. Cells_NNP were_VBD fixed_VBN with_IN glutaraldehyde_NN and_CC stained_JJ
          for_IN the_DT expression_NN of_IN the_DT 
          lac_NN Z_NNP gene_NN as_IN described_VBN above_IN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        D_NNP ._. A_DT ._. H_NNP ._. performed_VBD the_DT experiments_NNS described_VBD in_IN this_DT paper_NN
        and_CC drafted_VBD the_DT manuscript_NN ._. M_NNP ._. W_NNP ._. P_NN ._. and_CC T_NN ._. S_NNP ._. conceived_VBD the_DT
        study_NN and_CC participated_VBD in_IN its_PRP$ design_NN and_CC development_NN ._. All_DT
        authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
